Skip to main content

Gilead Sciences, Inc.

corporate_fare Company Profile

Gilead Sciences, Inc.

GILD·NASDAQ·Life Sciences·CIK 0000882095

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering innovative medicines to prevent and treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. The company operates in more than 35 countries worldwide, with its headquarters in Foster City, California. In 2025, Gilead's commercial portfolio included over 25 therapies. Key products with approved indications in the U.S. include: In HIV, Biktarvy® is a once-daily oral single-tablet regimen for HIV-1 infection, combining bictegravir, emtricitabine (FTC), and tenofovir alafenamide (TAF). Descovy® is an oral formulation used with other antiretroviral agents for HIV-1 infection and is also FDA-approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in certain patients. Descovy is a fixed-dose combination of FTC and TAF. Genvoya® is a once-daily oral single-tablet regimen for HIV-1 infection, combining elvitegravir, cobicistat, FTC, and TAF. Odefsey® is a once-daily oral formulation for the treatment of HIV-1 infection in certain patients.

Gilead Sciences, Inc. (NASDAQ:GILD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 47 items for GILD at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Gilead's Livdelzi Phase 3 Study Shows Sustained Efficacy, No New Safety Concerns
  • FDA Approves Gilead's First-Ever Chronic HDV Drug for U.S. Market
  • Gilead's Trodelvy Nears EU Approval for First-Line Triple-Negative Breast Cancer
  • Gilead Acquires Tubulis for $3.15B Upfront, Bolstering Oncology Pipeline
  • Gilead Finalizes $3.15B Tubulis Acquisition, Adds Key Oncology ADC Assets

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$29.44B
Net Income
$8.51B
Diluted EPS
$6.78
Op. Cash Flow
$10.02B
Free Cash Flow
$9.46B
Gross Profit
$23.21B
Operating Income
$10.02B
Cash & Equivalents
$7.56B
Total Debt
$24.94B
Debt / Equity
1.10×
Net Margin
28.9%
Shares Outstanding
1.24B sh
Source: 10-K · filed 2026-02-24 · accession 0000882095-26-000006
$167.58 +0.69% today
52-week range · as of 2026-10-29 $114.02 – $167.58
Market cap
$206.43B
Volume
7.6M (1.2× avg)
3-mo avg 6.4M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GILD - Filings & News (Page 2)

GILD
May 27, 2026, 3:39 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $133.50
Real-time Price: $167.58 info
Change: +$34.08 (+26%) info
Market Cap: $206.43B info
GILD
May 22, 2026, 2:26 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $134.17
Real-time Price: $167.58 info
Change: +$33.41 (+25%) info
Market Cap: $206.43B info
GILD
May 22, 2026, 8:13 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $131.18
Real-time Price: $167.58 info
Change: +$36.40 (+28%) info
Market Cap: $206.43B info
GILD
May 22, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $131.18
Real-time Price: $167.58 info
Change: +$36.40 (+28%) info
Market Cap: $206.43B info
GILD
May 21, 2026, 9:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $129.80
Real-time Price: $167.58 info
Change: +$37.78 (+29%) info
Market Cap: $206.43B info
GILD
May 20, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $130.69
Real-time Price: $167.58 info
Change: +$36.89 (+28%) info
Market Cap: $206.43B info
GILD
May 14, 2026, 5:22 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $132.24
Real-time Price: $167.58 info
Change: +$35.34 (+27%) info
Market Cap: $206.43B info
GILD
May 14, 2026, 5:11 PM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $132.24
Real-time Price: $167.58 info
Change: +$35.34 (+27%) info
Market Cap: $206.43B info
GILD
May 08, 2026, 5:00 PM EDT
Filing Type: 13F-HR
Importance Score:
7
Price at Filing: $131.33
Real-time Price: $167.58 info
Change: +$36.25 (+28%) info
Market Cap: $206.43B info
GILD
May 07, 2026, 5:12 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $130.50
Real-time Price: $167.58 info
Change: +$37.08 (+28%) info
Market Cap: $206.43B info
GILD
May 07, 2026, 4:03 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $133.25
Real-time Price: $167.58 info
Change: +$34.33 (+26%) info
Market Cap: $206.43B info
GILD
May 07, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $130.99
Real-time Price: $167.58 info
Change: +$36.59 (+28%) info
Market Cap: $206.43B info
GILD
May 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $132.75
Real-time Price: $167.58 info
Change: +$34.83 (+26%) info
Market Cap: $206.43B info
GILD
Apr 29, 2026, 9:41 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $128.76
Real-time Price: $167.58 info
Change: +$38.82 (+30%) info
Market Cap: $206.43B info
GILD
Apr 28, 2026, 8:56 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $128.92
Real-time Price: $167.58 info
Change: +$38.66 (+30%) info
Market Cap: $206.43B info
GILD
Apr 28, 2026, 8:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $129.00
Real-time Price: $167.58 info
Change: +$38.58 (+30%) info
Market Cap: $206.43B info
GILD
Apr 17, 2026, 8:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $139.00
Real-time Price: $167.58 info
Change: +$28.58 (+21%) info
Market Cap: $206.43B info
GILD
Apr 14, 2026, 1:40 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $140.07
Real-time Price: $167.58 info
Change: +$27.51 (+20%) info
Market Cap: $206.43B info
GILD
Apr 13, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $138.56
Real-time Price: $167.58 info
Change: +$29.02 (+21%) info
Market Cap: $206.43B info
GILD
Apr 07, 2026, 8:19 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $139.27
Real-time Price: $167.58 info
Change: +$28.31 (+20%) info
Market Cap: $206.43B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets